---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-067452"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:21:54.944375+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics Q1 net income $3.7M, revenue $22.1M; reaffirms FY2025 guidance $118–128M

## Summary
- Net income $3.7M ($0.03 basic EPS) vs $9.9M in Q1 2024; revenue $22.1M, down 19% due to ETUARY decline from prior year one-time campaign.
- FY2025 revenue guidance reiterated at $118–128M (2024: $105.8M); commercial launches of nintedanib (May 2025) and avatrombopag (March 2025) expected to drive H2 growth.
- Phase 3 Hydronidone trial for CHB liver fibrosis completed data lock; topline results expected Q2 2025. IND approved for pirfenidone for radiation-induced lung injury.
- Non-GAAP adjusted net income $2.9M vs $8.2M; cash $51.3M as of March 31, 2025.

## SEC filing metadata
- accession: 0000950170-25-067452
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/0000950170-25-067452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/gyre-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-067452
- JSON: https://secwatch.observer/filing/0000950170-25-067452.json
- Plain text: https://secwatch.observer/filing/0000950170-25-067452.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.